Alnylam Pharma Guides - Analyst Blog
Alnylam Pharmaceuticals, Inc. (ALNY) recently provided an update on its key pipeline, scientific and business goals for the next 12 to 18 months coupled with financial guidance for 2010.
Alnylam, which focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi), intends to advance ALN-RSV01 to a new mid-stage trial for treating respiratory syncytial virus (RSV). Alnylam expects to start enrolling patients for the study in the first quarter of 2010. ALN-RSV01 is the most advanced pipeline candidate of the company. Alnylam will also advance the development of its other candidates, which are in early-stage or preclinical development. Alnylam expects to have at least four RNAi therapeutics programs under clinical development by the end of 2010.
The company is utilizing the potentially revolutionary RNA interference technology, designed to stop the genetic causes of illnesses by turning off proteins at the root of the disease, to build a pipeline of drug candidates to treat a wide array of diseases such as RSV, Parkinson’s disease (PD), cystic fibrosis (CF) and spinal cord injury. The company intends to broaden the scope of its scientific leadership by significantly expanding the range of tissues and cell types targeted by RNAi therapeutics by the end of 2010.
Alnylam has entered into collaborations or deals with big pharmaceutical players like Novartis (NVS), Biogen Idec (BIIB), Roche, Takeda to further develop and utilize its core technology. The partnerships with major players further validate the potential and viability of the RNAi approach.
Alnylam expects to have a cash balance in excess of $430 million as of Dec 31, 2009. The company expects to end 2010 with a cash balance in excess of $325 million. This forecast is exclusive of any potential payment from Novartis.
Currently we are Neutral on Alnylam Pharmaceuticals.
Read the full analyst report on "ALNY"
Read the full analyst report on "NVS"
Read the full analyst report on "BIIB"
Zacks Investment Research
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
